You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)

Article info

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)

Authors

Citation

Gossage D, Cieslarova B, Ap S, et al
SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)
Annals of the Rheumatic Diseases 2016;75:723-724.

Publication history

  • First published July 15, 2016.
Online issue publication 
July 15, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions